ENTO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENTO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Entero Therapeutics's tax expense for the months ended in Mar. 2024 was $-14.86 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-14.86 Mil.
The historical data trend for Entero Therapeutics's Tax Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entero Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Tax Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Entero Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Tax Expense | Get a 7-Day Free Trial | - | - | - | - | -14.86 |
Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.
Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entero Therapeutics (NAS:ENTO) Tax Expense Explanation
In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.
Thank you for viewing the detailed overview of Entero Therapeutics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
James Sapirstein | director, officer: President and CEO | 1517 SAN JACINTO, HOUSTON TX 77002 |
Sarah Romano | officer: Chief Financial Officer | 271 WAVERLY OAKS ROAD, WALTHAM MA 02452 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
David Andrew Hoffman | director | 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431 |
Edward Borkowski | director | 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317 |
Mary Theresa Coelho | director | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Alastair Riddell | director | C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226 |
Vern Lee Schramm | director | 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461 |
Gregory Oakes | director | 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226 |
James Pennington | officer: CHIEF MEDICAL OFFICER | 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545 |
Daniel H Schneiderman | officer: CHIEF FINANCIAL OFFICER | 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226 |
Ross Edmund Burke Jr. | 10 percent owner | C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196 |
Johan M. Spoor | director, officer: President and CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Maged Shenouda | director | 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011 |
Pelican Partners Llc | 10 percent owner | PO BOX 2422, WESTPORT CT 06880 |
From GuruFocus
By Marketwired • 10-03-2023
By Marketwired • 05-16-2024
By GlobeNewswire • 12-27-2023
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 09-15-2023
By GuruFocus Research • 02-07-2024
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 06-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.